LEHI, Utah--(BUSINESS WIRE)--Frelii, Inc. (OTCQB: FRLI) (“Frelii” or “the Company”) was notified by OTC Markets (“OTC”) on May 14, 2019 of recent trading and promotional activity regarding its common stock. The Company has been informed that this may have resulted in a higher-than-average trading volume in the Company's stock. The Company was informed that newsletter and emails were sent from a non-affiliated third party source.
The Company had no knowledge of the unauthorized promotional activity until it was notified by OTC Markets and given a copy of the material. It was not involved, directly or indirectly, with the creation, distribution or payment of the promotional materials related to the Company and its security. The Company had no awareness or editorial control over the content in the materials.
Upon conducting due diligence inquiries regarding the unauthorized promotional activity, the Company has determined that the content of the promotions contains incomplete and unvetted information with speculative language regarding the Company’s business performance and its shares. The Company encourages those interested in the Company to rely solely on information included in its press releases and its filings and disclosures made with the S.E.C. (through the EDGAR Database) and OTC Markets Group.
After inquiry of management, the Company confirms that its officers, directors and controlling shareholders (i.e., shareholders owning 10% or more of the Company's securities), have not sold or purchased the Company's securities within the past 90 days on the open market.
Since December, 2018, the Company has engaged Springboard5 for PR and IR activities.
The Company has not at any point issued shares or convertible instruments allowing conversion to equity securities at prices constituting a discount to the current market rate at the time of the issuance.
About Frelii, Inc.
Frelii, Inc. is a biotech company that uses human DNA gene sequencing and artificial intelligence (AI) to assess more than 3.2 billion markers on the human genome. The results are aligned and leveraged against its AI, as a means of creating a very strong and powerful data platform for use by the Health & Wellness, Healthcare, Medical Cannabis and Pharmaceutical industries. Frelii’s technology generates accurate and profoundly valuable insight into an individual’s DNA. The company provides DNA Kit Packages and customized reporting for consumers, patients and healthcare providers to ensure the ideal treatment, drugs and dosing are a prime “fit” to the individual. For more information, please visit www.frelii.com. Frelii (OTCQB: FRLI) trades on the #OTCQB Venture Market for early stage and developing U.S. and international companies. Companies are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on www.otcmarkets.com.
Follow Frelii online at:
Frelii Facebook Page https://www.facebook.com/livefrelii/
Frelii Twitter Feed @livefrelii
Frelii Instagram Page @livefrelii
Frelii LinkedIn Page linkedin.com/company/frelii/
Safe Harbor Statement:
This release contains certain “forward-looking statements” relating to the business of the Company. All statements, other than statements of historical fact included herein are “forward-looking statements” including statements regarding: the continued growth of the e-commerce segment and the ability of the Company to continue its expansion into that segment; the ability of the Company to attract customers and partners and generate revenues; the ability of the Company to successfully execute its business plan; the business strategy, plans, and objectives of the Company; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions and involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume any duty to update these forward-looking statements.